Markets:

Overview

News

Currencies

International

Treasuries

Revvity, Inc. Common Stock (NY:RVTY)

105.08 +3.02 (+2.96%)

Streaming Delayed Price Updated: 2:46 PM EST, Jan 6, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Revvity, Inc. Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >

What's Going On With Revvity Stock Today? ↗

April 02, 2025

Revvity's stock rose after FDA approval of its Auto-Pure 2400 platform integrated with the T-SPOT.TB test, improving latent TB detection efficiency in labs.

Via Benzinga

Revvity Secures FDA Approval for Improved Automated Latent Tuberculosis Test

April 02, 2025

From Revvity

Via Business Wire

1 Healthcare Stock to Target This Week and 2 to Turn Down

March 31, 2025

Personal health and wellness is one of the many secular tailwinds for healthcare companies. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed the...

Via StockStory

Topics Stocks

What Does the Market Think About Revvity? ↗

March 04, 2025

Via Benzinga

(RVTY) - Analyzing Revvity's Short Interest ↗

January 22, 2025

Via Benzinga

Is Revvity Gaining or Losing Market Support? ↗

March 27, 2025

Via Benzinga

How Tariffs Are Rocking The 'Bubblegum And Shoestring' Medical Supply Chain ↗

March 27, 2025

Uncertainty has cast a pall over medical stocks, which are taking a "wait-and-see" approach to Trump's tariffs.

Via Investor's Business Daily

Topics Government

Maryland Rep. April McClain Delaney Sold Over $54K Worth of A.O. Smith Stock: Here's What You Should Know ↗

March 21, 2025

Via Benzinga

Stay informed with the top movers within the S&P500 index on Wednesday. ↗

March 19, 2025

Stay updated with the movements of the S&P500 index one hour before the close of the markets on Wednesday. Discover which stocks are leading as top gainers and losers in today's session.

Via Chartmill

Forecasting The Future: 7 Analyst Projections For Revvity ↗

January 21, 2025

Via Benzinga

Revvity Expands Alliance with Genomics England to Drive Research into Newborn Genomic Sequencing in England

March 20, 2025

From Revvity

Via Business Wire

Explore the top gainers and losers within the S&P500 index in today's session. ↗

March 19, 2025

Let's have a look at what is happening on the US markets in the middle of the day on Wednesday. Below you can find the top S&P500 gainers and losers in today's session.

Via Chartmill

Which S&P500 stocks are gapping on Wednesday? ↗

March 19, 2025

Stay updated with the S&P500 gap up and gap down stocks on Wednesday. Get a glimpse of the market's movement during today's session.

Via Chartmill

Revvity’s EUROIMMUN Receives CE Mark for Novel Measles Antibody Detection Assay

March 03, 2025

From Revvity

Via Business Wire

Winners And Losers Of Q4: Revvity (NYSE:RVTY) Vs The Rest Of The Research Tools & Consumables Stocks

March 03, 2025

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Revvity (NYSE:RVTY) and the best and worst...

Via StockStory

Topics Economy

3 Reasons to Sell RVTY and 1 Stock to Buy Instead

February 28, 2025

Over the past six months, Revvity’s shares (currently trading at $111) have posted a disappointing 8.5% loss, well below the S&P 500’s 5.1% gain. This was partly due to its softer quarterly results and...

Via StockStory

Topics Stocks

Revvity Wins Permanent Injunction Enforcing Agreements with Cloud Software Group

February 20, 2025

From Revvity

Via Business Wire

Revvity to Present at Upcoming Investor Conferences

February 20, 2025

From Revvity

Via Business Wire

Uncover the latest developments among S&P500 stocks in today's session. ↗

February 10, 2025

Curious about the top performers within the S&P500 index in the middle of the day on Monday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.

Via Chartmill

Revvity (NYSE:RVTY) Reports Q4 In Line With Expectations

January 31, 2025

Life sciences company Revvity (NYSE:RVTY) met Wall Street’s revenue expectations in Q4 CY2024, with sales up 4.8% year on year to $729.4 million. On the other hand, the company’s full-year revenue...

Via StockStory

Friday's pre-market session: top gainers and losers in the S&P500 index ↗

January 31, 2025

Get insights into the top gainers and losers in the S&P500 index of Friday's pre-market session.

Via Chartmill

Revvity Announces Financial Results for the Fourth Quarter and Full Year of 2024

January 31, 2025

From Revvity

Via Business Wire

Earnings Scheduled For January 31, 2025 ↗

January 31, 2025

Via Benzinga

Revvity Board Declares Quarterly Dividend

January 23, 2025

From Revvity

Via Business Wire

Revvity and Element Biosciences Collaborate to Advance Sequencing-based IVD Neonatal Testing

January 13, 2025

From Revvity

Via Business Wire

Revvity to Hold Earnings Call on Friday, January 31, 2025; Provides Update on Financial Performance

January 12, 2025

From Revvity

Via Business Wire

Revvity Announces FDA Clearance for First Automated Free Testosterone Test

January 10, 2025

From Revvity

Via Business Wire

Revvity to Present at J.P. Morgan Healthcare Conference

December 17, 2024

From Revvity

Via Business Wire

Despite Higher Valuations, Some Life Sciences Tools Stocks Create Good Opportunities: Analyst ↗

December 13, 2024

BofA upgrades Danaher and Revvity, predicting a mixed but improving outlook for life sciences tools in fiscal year 2025 amid ongoing market challenges.

Via Benzinga

Revvity Broadens Relationship with Genomics England to Advance Genomics in the UK

November 20, 2024

From Revvity

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.